A Study of the Safety and Efficacy of Synvisc in Patients With Symptomatic Shoulder Osteoarthritis

This study has been completed.
Sponsor:
Information provided by:
Genzyme, a Sanofi Company
ClinicalTrials.gov Identifier:
NCT00131300
First received: August 17, 2005
Last updated: August 3, 2009
Last verified: November 2006
  Purpose

This clinical study is to evaluate the safety and efficacy of Synvisc in patients with symptomatic shoulder osteoarthritis (OA). Patients will be given Synvisc, with the possible administration of a second injection where insufficient symptomatic pain relief was experienced during the 3 month follow up period.


Condition Intervention Phase
Osteoarthritis
Musculoskeletal Diseases
Device: Synvisc (hylan G-F 20)
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Genzyme, a Sanofi Company:

Primary Outcome Measures:
  • Pain relief

Study Start Date: April 2004
Estimated Study Completion Date: February 2006
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with symptomatic OA pain of shoulder (gleno-humeral)

Exclusion Criteria:

  • Patients with current or prior conditions or treatment that would impede measurement of efficacy or safety
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00131300

Locations
France
Hopital Ambroise Pare
Boulogne-Billancourt, France, 92100
Clinique Saint Anne Lumiere
Lyon, France, 69003
Centre de Medecine et Traumatologie du Sport Clinique du Sport
Merignac, France, 33700
CHRU Hopital Trousseau
Tours, France, 37044
Germany
August-Viktoria-Klinik
Bad Oeynhausen, Germany, 32545
Universitatsklinik und Poliklinik Orthopadie & Physikalische Medizin
Halle/Saale, Germany, 06097
Sponsors and Collaborators
Genzyme, a Sanofi Company
Investigators
Study Director: Medical Monitor Genzyme, a Sanofi Company
  More Information

No publications provided

Responsible Party: Medical Monitor, Genzyme Corporation
ClinicalTrials.gov Identifier: NCT00131300     History of Changes
Other Study ID Numbers: SYNV-002-01
Study First Received: August 17, 2005
Last Updated: August 3, 2009
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Genzyme, a Sanofi Company:
Osteoarthritis of the shoulder
Musculoskeletal

Additional relevant MeSH terms:
Musculoskeletal Diseases
Osteoarthritis
Arthritis
Joint Diseases
Rheumatic Diseases

ClinicalTrials.gov processed this record on July 20, 2014